ABCA4 and glioblastoma: The limited efficacy of dasatinib was attributed to poor accumulation in the brain due to the activity of ATP-binding cassette transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein which are highly expressed on the blood-brain barrier (BBB) and glioblastoma cells [45, 46].